Verastem Inc (NASDAQ:VSTM) Rating Reiterated by Jefferies Group LLC

Cornelia Mascio
Luglio 17, 2017

According to the analysts, Verastem Inc (NASDAQ:VSTM) is expected to announce $-0.34/share EPS for the current quarter. Tracking the stock price in relation to moving averages as well as highs and lows for the year might assist with evaluating future stock performance. Zacks Investment Research's target price suggests a potential downside of 8.31% from the stock's current price. The Company is focused on discovering and developing drugs to improve outcomes for patients with cancer. The Company operates in the segment of developing drugs for the treatment of cancer.

Verastem, Inc is a biopharmaceutical company.

A number of research firms have recently weighed in on VSTM.

The move comes after 6 months negative chart setup for the $138.43 million company. Cann reiterated a "buy" rating and set a $6.00 price target on shares of Verastem in a research report on Monday, June 26th. Zacks Investment Research upgraded shares of Verastem from a "hold" rating to a "buy" rating and set a $3.75 price objective for the company in a research note on Thursday. Finally, Jefferies Group LLC reiterated a "hold" rating and issued a $1.50 price target on shares of Verastem in a report on Wednesday, June 28th. It is meant to chart the current and historical strength or weakness of a stock or market based on the closing prices of a recent trading period. H.C. Wainwright maintained it with "Buy" rating and $6.50 target in Friday, March 24 report. About 1.30 million shares traded. 278,809 shares of the company traded hands.

Shares of Verastem Inc (NASDAQ:VSTM) now have an Average Brokerage Recommendation of 1.75, number of Recs in ABR is 4 while industry rank of the company by ABR is out of 265. The company has market cap of $144.96 million.

Consequently Verastem Inc (NASDAQ:VSTM)'s weekly and monthly volatility is 20.11%, 13.17% respectively. The biopharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.35).

WARNING: This piece was originally reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this article on another publication, it was illegally stolen and reposted in violation of United States & global trademark & copyright legislation. The stock was acquired at an average cost of $2.45 per share, with a total value of $73,500.00. Following the acquisition, the director now directly owns 69,462 shares of the company's stock, valued at $170,181.90. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Several large investors have recently made changes to their positions in the company. FMR LLC boosted its position in Verastem by 32.2% in the fourth quarter. FMR LLC now owns 901,200 shares of the biopharmaceutical company's stock worth $1,009,000 after buying an additional 219,445 shares during the period. Renaissance Technologies LLC now owns 1,022,200 shares of the biopharmaceutical company's stock worth $1,145,000 after buying an additional 122,600 shares during the last quarter.

Verastem, Inc is a biopharmaceutical company.

Altre relazioniGrafFiotech

Discuti questo articolo

Segui i nostri GIORNALE